Candriam S.C.A. Has $46.53 Million Stake in BioNTech SE (NASDAQ:BNTX)

Candriam S.C.A. increased its position in BioNTech SE (NASDAQ:BNTX) by 261.2% in the second quarter, Holdings Channel.com reports. The firm owned 578,998 shares of the company’s stock after acquiring an additional 418,695 shares during the period. Candriam S.C.A.’s holdings in BioNTech were worth $46,526,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares in the last quarter. CWM LLC raised its position in shares of BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after purchasing an additional 217 shares during the period. Frazier Financial Advisors LLC acquired a new position in shares of BioNTech in the 4th quarter valued at approximately $30,000. Covestor Ltd increased its stake in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Down 0.2 %

BioNTech stock opened at $89.94 on Friday. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average price is $84.65 and its two-hundred day moving average price is $89.25. The firm has a market capitalization of $21.38 billion, a price-to-earnings ratio of 179.88 and a beta of 0.23. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $121.39.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the previous year, the company earned ($0.86) EPS. The business’s revenue was down 23.3% compared to the same quarter last year. On average, equities research analysts predict that BioNTech SE will post -2.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BNTX. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. TD Cowen dropped their target price on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $113.00 price target on shares of BioNTech in a research report on Tuesday, August 27th. Evercore ISI assumed coverage on shares of BioNTech in a research report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price objective on the stock. Finally, JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $94.00 to $91.00 and set an “underweight” rating for the company in a research report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $109.09.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.